TL;DR

Science minister Chris McDonald used an FT pharma summit on Wednesday 11 November to argue that NHS records should become “a very powerful driver for investment” in AI-led drug discovery. He called the combination of the health service’s long-running data and Britain’s AI sector a “strategic competitive advantage”. He also conceded the plan depends on keeping public trust, which recent controversies over Palantir and UK Biobank have tested.

The pitch

McDonald, a minister in two departments, business and health, said no other country could reproduce the depth of the UK’s health records gathered over decades. Speaking at the FT’s annual pharma and biotech event, he called the UK’s AI industry “at least the third best in the world” and said “the future of medicines discovery … depends on AI”.

According to the FT, he confirmed that the push to commercialise NHS data begun under Sir Keir Starmer, which has unsettled some Labour MPs, will carry on under Andy Burnham.

The trust problem

The minister said he was “very aware” that the strategy relies on “leveraging the trust and confidence in the NHS brand”. The FT puts that alongside two live concerns: Palantir’s place in the NHS, and incidents such as UK Biobank patient data being offered for sale. McDonald’s answer was “governance and assurance”, pointing to how ministers pushed UK Biobank to pause access after that breach.

The FT has reported that Palantir’s NHS contract is due to be extended by two years while a new procurement, weighted towards UK tech sovereignty, takes place. Some in government, the paper says, see moving away from Palantir as necessary to keep voters on side.

Why it matters

We recently reported that Palantir lobbied a minister about GP records, which shows how contested the question of who handles NHS data has become. McDonald’s remarks make the government’s position plain: it wants to use the data more, not less. In our view the hard part is not the ambition but the sequencing. Pharma firms will invest on the strength of access rules, while patients will judge the scheme on breaches and on which companies get in.

Looking Forward

McDonald did not set out new rules for data access. The FT says he also defended April’s US deal that lifted NHS prices for new medicines, which carries a £1bn bill for the NHS over three years. His argument was that the cost lands on the health service while the gain shows up elsewhere, mainly as tax revenue for the Treasury.